Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From a closing market price of $103.44 per share on December 19, 2024, Novo's ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

(This story has been corrected to say that the trial is to test long-term efficacy, not the late-stage CagriSema trial planned after data in December, in headline and paragraphs 1and 2) Sign up here.

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...